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Abstract: AIM The aim of this study was to evaluate the predictive value of ￿-fetoprotein in maternal
serum (MS-AFP) as a marker for diverse pregnancy outcomes. METHODS The study was based on preg-
nancy and delivery data from 5520 women between 1999 and 2014 at University Hospital of Zurich (UHZ).
INCLUSION CRITERIA both MS-AFP and pregnancy outcome were known for the same pregnancy.
Pregnancy outcomes and characteristics such as fetal malformation, intrauterine fetal death (IUFD) and
intrauterine growth retardation as well as maternal age, weight before pregnancy, gestational age (GA)
at delivery, newborn weight, length and head circumference were analyzed with respect to the MS-AFP
value. MS-AFP value was categorized into three groups: elevated MS-AFP>2.5 multiples of the median
(MoM), normal 0.5-2.49 MoM and decreased <0.5 MoM. RESULTS Newborn weight (g) and length (cm)
were significantly lower in the elevated MS-AFP (P<0.001) group, and infants had 1 week lower GA at
delivery (P<0.05). In the group of elevated MS-AFP (n=46), 26.1% of pregnancies were significantly
related to adverse pregnancy outcomes, such as fetal malformations, fetuses small for gestational age
(SGA) and IUFD. Adverse pregnancy outcomes of 5.6% were registered in the group of normal MS-AFP
and 7.3% in the group of low MS-AFP (P<0.05). CONCLUSION MS-AFP level in the second trimester
is still an important indicator of fetal surface malformations; however, ultrasound still outweighs as a
screening method. Nevertheless, pregnant women with elevated MS-AFP values and with no sonographi-
cally detected fetal malformations should additionally receive the third trimester ultrasound examination
to exclude other possible complications of pregnancy.
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Abstract
Aim: The aim of this study was to evaluate the predictive 
value of α-fetoprotein in maternal serum (MS-AFP) as a 
marker for diverse pregnancy outcomes.
Methods: The study was based on pregnancy and deliv-
ery data from 5520 women between 1999 and 2014 at Uni-
versity Hospital of Zurich (UHZ). Inclusion criteria: both 
MS-AFP and pregnancy outcome were known for the same 
pregnancy. Pregnancy outcomes and characteristics such 
as fetal malformation, intrauterine fetal death (IUFD) and 
intrauterine growth retardation as well as maternal age, 
weight before pregnancy, gestational age (GA) at delivery, 
newborn weight, length and head circumference were 
analyzed with respect to the MS-AFP value. MS-AFP value 
was categorized into three groups: elevated MS-AFP > 2.5 
multiples of the median (MoM), normal 0.5–2.49 MoM and 
decreased < 0.5 MoM.
Results: Newborn weight (g) and length (cm) were signifi-
cantly lower in the elevated MS-AFP (P < 0.001) group, and 
infants had 1 week lower GA at delivery (P < 0.05). In the 
group of elevated MS-AFP (n = 46), 26.1% of pregnancies 
were significantly related to adverse pregnancy outcomes, 
such as fetal malformations, fetuses small for gestational 
age (SGA) and IUFD. Adverse pregnancy outcomes of 5.6% 
were registered in the group of normal MS-AFP and 7.3% in 
the group of low MS-AFP (P < 0.05).
Conclusion: MS-AFP level in the second trimester is still an 
important indicator of fetal surface malformations; how-
ever, ultrasound still outweighs as a screening method. 
Nevertheless, pregnant women with elevated MS-AFP 
values and with no sonographically detected fetal mal-
formations should additionally receive the third trimester 
ultrasound examination to exclude other possible compli-
cations of pregnancy.
Keywords: Intrauterine fetal death; intrauterine fetal 
growth retardation; maternal serum AFP; pregnancy 
outcome; small for gestational age.
Introduction
The era of prenatal screening for life-threatening congeni-
tal anomalies began in the 1970s with the investigation of 
increased levels of α-fetoprotein (AFP) in amniotic fluid 
and maternal serum in pregnancies affected by fetal open 
neural tube defects (NTDs) [1]. Since then AFP-Test has 
been part of routine prenatal preventive care, at least in 
more economically developed countries.
AFP is a glycoprotein, member of the albu minoid 
gene family [2, 3]. It is produced in early pregnancy by 
fetal liver and yolk sac [4]. AFP synthesis in the proliferat-
ing fetal liver in creases through the 20th week of gestation 
and thereafter remains fairly constant until the 32nd week 
[4, 5]. AFP is excreted into fetal urine and transported 
into maternal serum through the placenta or by diffusion 
across the fetal membranes [3]: leakage from fetal serum 
and cerebrospinal fluid (NTD); exposure of blood vessels 
in extruding viscera, leading to transudation of AFP; 
expedited protein filtration and passage into urine (con-
genital nephrosis); impaired fetal swallowing or digestion 
in amniotic fluid (GI anomaly) and altered or obstructed 
transplacental passage, such as in placenta accreta [6]. 
As a result, an elevated amount of AFP is estimated in 
maternal serum in case of open NTD, omphalocele, gas-
troschisis, congenital renal disease, esophageal atresia 
or fetal distress situations such as threatened abortion 
and fetal demise. Nevertheless, rise of AFP concentra-
tion may be observed in multiple pregnancies [7]. AFP 
level might also be influenced by gestational age (GA) at 
the time of assessment, maternal weight, racial origin, 
smoking, parity and in vitro fertilization [8, 9]. Increased 
AFP values were additionally registered at placenta-medi-
ated adverse pregnancy outcomes such as preeclampsia, 
intrauterine fetal growth restriction (IUGR), intrauterine 
fetal death (IUFD) abruptio placentae, preterm birth and 
oligohydramnios [10–16], possibly due to anomalies of 
placentation or ischemic placental disease [17]. As a result 
of placental hypoxia and apoptosis, some products of the 
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syncytiotrophoblast such as human chorionic gonadotro-
pin and inhibin A, as well as AFP, a product of the yolk 
sac and fetal liver, may reach the circulation in greater 
quantities than in normally developed placentas [18]. 
However, AFP regulat ing function during pregnancy and 
AFP involvement in the regulation of placental growth 
remains controversial and relatively unknown [15].
Due to ultrasound, diagnosis of the majority of NT and 
fetal surface defects is possible in early pregnancy; there-
fore, maternal serum alpha-fetoprotein (MS-AFP) screen-
ing is losing its value. Different countries have diverse 
regulations regarding MS-AFP.
In Canada it was already concluded that the primary 
use of MS-AFP for open/closed NTDs screening should 
be discontinued with the limited clinical exceptions of 
pregnant women with a pre-pregnancy body mass index 
> 35 kg/m2 or when geographical or clinical access factors 
limit timely and good quality ultrasound screening at 
18–22 weeks’ gestation [19]. MS-AFP testing is not required 
in the UK when the routine ultrasound screening is per-
formed [20]. In the USA, NTD screening is optional [21]. 
Swiss health insurance covers the screening of MS-AFP, 
which is optional in the second trimester.
Therefore, the aim of this study was to evaluate the 
predictive value of MS-AFP as a marker for possibly differ-
ent pregnancy outcomes and its use in the prenatal care.
Materials and methods
The retrospective cohort study comprised pregnancy and deliv-
ery data of 5520 women at the University Hospital of Zurich (UHZ) 
between 1999 and 2014. Pregnancies with the known outcomes and 
measured MS-AFP-value in the second trimester were included. 
Patients with multiple gestations and pregnancies with incomplete 
data were excluded from the study.
MS-AFP analysis was performed at UHZ between 13 and 18 
weeks of gestation and the costs were covered by health insurance. 
MS-AFP value > 2.5 multiples of the median (MoM) was defined as 
elevated, 0.5–2.49 MoM as normal and < 0.5 MoM as low. Fetal mal-
formations such as NTDs, surface defects, structural anomalies and 
genetic disorders or IUFD and small for gestational age newborns 
(SGA, newborn’s weight below or equal to the 5th percentile for GA 
according to local reference curves) were registered. Correlation 
between the MS-AFP value and pregnancy complications was ana-
lyzed. Newborns with malformations were excluded from the SGA 
group. Pregnancy characteristic such as maternal age, weight before 
pregnancy, GA at delivery, newborn weight, length and head circum-
ference were analyzed.
Statistical data analysis was performed using standard statisti-
cal programs (SPSS, Chicago, IL, USA; EXCEL, Redmond, WA, USA). 
The χ2 test was used to compare fetal malformations, IUFD and SGA 
in the groups of elevated, normal and low MS-AFP. The one-way 
analysis of variance (ANOVA) test was performed to evaluate the dif-
ferences of maternal age, weight before pregnancy, newborn weight, 
length, head circumference and GA in the determined AFP groups. A 
P-value of < 0.05 was considered statistically significant.
Results
Maternal and newborn characteristics are presented in 
Table 1. Any significant differences between AFP groups 
regarding maternal age, maternal weight, newborn weight 
percentile and length percentile as well as newborn head 
circumference were found. Newborn weight and length 
(P < 0.001) as well as GA at delivery (P < 0.05) were lower 
in the group of elevated AFP.
In the group of elevated MS-AFP (n = 46), 12 (26.1%) 
pregnancies were significantly related to adverse preg-
nancy outcomes, such as malformations, SGA and IUFD. 
Adverse pregnancy outcomes of 5.6% (n = 286) were regis-
tered in the group of normal and 7.3% (n = 10) in the group 
of low MS-AFP (P < 0.05).
The rate of IUFD was significantly higher in the 
group with elevated MS-AFP. Corresponding outcome was 
found in 21.7% (n = 10), 2.2% (n = 109) and 0.6% (n = 1) in 
elevated, normal and low MS-AFP groups (P < 0.00001), 
respectively. Distribution of adverse pregnancy outcomes 
Table 1: Maternal and newborn characteristics.
AFP value   > 2.49 MoM 
(n = 46)
  0.5–2.49 MoM 
(n = 5036)
  < 0.5 MoM 
(n = 138)
  P-value
Maternal age (years)   31.5  30.8  30.6  > 0.05
Maternal weight (kg)   64.7  65.5  71.5  > 0.05
Newborn weight (g)   2873  3274  3285  < 0.001
Newborn weight (‰)   46.3  53.4  55.5  > 0.05
Newborn length (cm)   46.8  49.0  48.9  < 0.001
Newborn length (‰)   48.5  53.5  55.0  > 0.05
Head circumference (cm)  33.8  34.4  34.7  > 0.05
GA (weeks)   37.4  38.6  38.5  < 0.05
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and fetal death regarding the MS-AFP value is presented 
in Table 2. Genetic disorders and spina bifida were found 
to be significantly more frequent in the group of elevated 
MS-AFP (P < 0.0001). However, there was no statistically 
significant difference between other malformations in 
different MS-AFP groups. Spina bifida and fetal surface 
defects in the groups of normal and decreased MS-AFP 
were also found. Significantly more SGA newborns were 
found in the group of elevated MS-AFP (P < 0.05).
Discussion
This study was performed to evaluate the predictive value 
of MS-AFP as a marker for screening possibly different 
pregnancy outcomes and its use in the prenatal care. 
Weight and length of newborns were lower in the group 
of an elevated AFP. Statistically significant differences 
were found only in grams and centimeters, but not in 
percentiles, probably because of lower GA. Significantly 
more malformations, especially spina bifida, and SGA 
newborns were found in the group of an elevated AFP 
too. On the other hand, spina bifida and surface defects 
were also found in the group of normal MS-AFP. In the 
group of elevated MS-AFP, significantly more IUFD were 
found. This difference between IUFD in different MS-AFP 
groups could be caused due to an increased count of 
fetal malformations in the group of elevated AFP and 
only one fetus with IUFD had no malformations. Results 
of the Yaron study [22] were different. It was noticed that 
pregnancies with unexplained mid-trimester elevation of 
MS-human chorionic gonadotropin (hCG) and/or MS-AFP 
were at increased risk of IUFD. The positive correlation 
between elevated MS-AFP level and SGA has already been 
described in the studies of Poon and Lesmes. They found 
that pregnant women with SGA neonates, in the absence 
of preeclampsia, had an increased uterine artery pulsatil-
ity index (UtA-PI) as well as MS-AFP levels at 19–24 weeks 
of gestation [23, 24]. The study of Barta et al. speculated 
that MS-AFP could be used as a marker for determina-
tion of fetal condition when following SGA fetuses [25]. 
Sharony et  al. [26] recently reported that MS-AFP and 
amniotic fluid AFP ratio might serve as a predictor of SGA 
and GA at delivery, and the higher the ratio, the lower the 
birth weight and GA. Although many of the associations 
between mid-trimester MS-hCG and/or MS-AFP levels and 
adverse pregnancy outcomes are statistically significant, 
the sensitivity and positive predictive value are too low for 
them to be clinically useful as screening tests. In the study 
of Dugoff [27], it was proposed that all women with unex-
plained elevation of mid-trimester MS-AFP levels should 
receive an increased fetal surveillance. It was suggested 
that ultrasonography is the most cost-effective approach 
and should be used as the initial diagnostic examina-
tion. However, the current retrospective study has some 
limitations. First of all, the study population with elevated 
MS-AFP was low. Furthermore, other maternal factors 
such as PIGF, MS-hCG and UtA-PI that could predict SGA 
were not analyzed.
In Switzerland, Canada, USA and UK, MS-AFP screen-
ing for NTDs is optional. It is universally agreed that 
ultrasound technology has better chances as a screening 
method; however, it may be worth to perform MS-AFP 
screening test for NTDs in addition to ultrasound, espe-
cially in teaching hospitals, where the young examiners 
are inexperienced. This combined screening approach 
could help avoid missed NTDs and other fetal surface 
defects. MS-AFP included in “combined” screening tests 
could also alert an increased risk of adverse pregnancy 
Table 2: Distribution of adverse pregnancy outcome and fetal death regarding the MS-AFP value.
MS-AFP value   > 2.49 MoM  0.5–2.49 MoM  < 0.5 MoM  P-value
n = 5220   46 (0.9%)  5036 (95.9%)  138 (3.2%) 
SGA   5 (10.9%)  231 (4.4%)  < 0.05
Hydrops   0  3  0 
Fetal malformation count  7 (15.2%)  60 (1.2%)  2 (1.4%)  < 0.0001
-Genetic disorders   3 (42.9%)  6 (9.5%)  0  < 0.0001
-Spina bifida   2 (28.6%)  2 (3.2%)  0  < 0.0001
-Surface defects   0  9  1 
-Brain malformations   1  8  0 
-Cardiac malformations   0  9  0 
-Kidney malformations   0  9  0 
-Multiple malformations   1  3  0 
-Other malformations   0  14  1 
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outcomes in the third trimester. We suggest that pregnant 
women with an elevated mid-trimester MS-AFP value, but 
without any fetal malformations detected by ultrasound 
at the 20–24 weeks of gestation, should receive an addi-
tional third trimester ultrasound examination, to exclude 
IUGR and other adverse pregnancy outcomes.
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